Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 122

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 122
---
.

Figure 6

Figure 6: Aptorum’s
technology successfully confirmed a known Hepatitis B diagnosis in a bio banked sample.

Case Study #2A patient was undergoing
chemotherapy and developed a severe lung infection that was refractory to first-line antibiotics but eventually responded to the traditional
trial and error approach. Using our technology, we found that 10% of all reads came from Leuconostoc, a Gram+ bacteria (Figure 7). Importantly,
Leuconostoc was not identified by physicians, demonstrating that our technology can identify pathogens that allude a traditional diagnosis.

Figure 7

Figure 7: Aptorum’s
technology identified pathogen(s) that allude the traditional diagnostic approach.

PathsDxTest has
the revolutionary potential to cover simultaneously over 1300 pathogens due to the unbiased approach in analyzing pathogen genome information
and caters to patients who are infected with multi-strains of pathogen. The technology can be updated through our software analytics on
an ongoing basis as further pathogenic genome sequences are updated through public databases, ensuring g that it is up-to-date on new
and emerging pandemic threats.

PathsDxTest is
currently undergoing Clinical Validation to confirm the performance of PathsDxTest using clinical/patient samples. PathsDxTest commenced clinical validations and will continue to undergo validations in parallel with its pre-commercialization process.

Patent License and Application

On September 25, 2020, the
Company’s subsidiary, Paths Diagnostics Pte. Limited, entered into an exclusive licence agreement with Accelerate Technologies Pte
Ltd, the commercialization arm of the Singapore’s Agency for Science, Technology and Research (“ A*STAR”), to co-develop
PathsDxTest, a novel molecular-based rapid pathogen identification and detection diagnostics technology. No upfront fee or
royalty on net sales is payable under the license agreements, although we are required to pay a mid-teens to mid-twenties percentage of
sublicense revenue that we receive from our sublicensees, if any. In addition, we agreed to pay to the licensor aggregate development
milestones of up to US$250,000. When specific development milestone is reached, we are also required to satisfy certain diligence obligations,
including recruitment of staff, establishment of relationship with potential customers and exercise commercially reasonable efforts in
selling the Licensed Products.

Two (2) US provisional patent applications and one (1) Singapore patent
application was filed in 2021, but subsequently abandoned